Is Anifrolumab safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Anifrolumab. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. A woman with systemic lupus erythematosus was treated with prednisolone 6 to 6.5 mg, tacrolimus 4 mg, and hydroxychloroquine 300 mg daily and anifrolumab 300 mg every 4 weeks. Milk samples taken between days 1 and 14 after resuming anifrolumab postpartum ranged from 0.01 to 0.11 mg/L, with the highest concentration 4 days after the dose.[ 4 ] Infant Levels. Relevant published information was not found as of the revision date.
“No published information” means the studies do not exist yet — not that Anifrolumab is known to be harmful, and not that it is known to be safe. Your prescriber or pharmacist can weigh your baby's age and whether a better-studied alternative would do the same job. Worth asking before stopping a medicine you need.
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.